(R) -AR-13503

(R) -AR-13503 ((R) -AR-13324 M1 metabolite) is the the (R) -enantiomer of AR-13503 (HY-12798C) . AR-13503 is the hydrolytic metabolite of AR-13324 mesylate. AR-13324 is a ROCK kinase and PKC inhibitor with anti-angiogenic and retinal health-improving effects, showing potential for use in retinal disease research[1][2][3].

Product Specifications

CAS Number

[2377238-62-3]

Product Name Alternative

(R) -AR-13324 M1 metabolite

UNSPSC

12352005

Target

Drug Metabolite; PKC; ROCK

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; Metabolic Enzyme/Protease; Stem Cell/Wnt; TGF-beta/Smad

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Purity

98.20

Smiles

OCC1=CC=C([C@H](CN)C(NC2=CC(C=CN=C3)=C3C=C2)=O)C=C1

Molecular Formula

C19H19N3O2

Molecular Weight

321.37

References & Citations

[1]Ding J, et al. ROCK/PKC inhibitor AR-13503 inhibits angiogenesis and protects the barrier function of retinal pigment epithelium[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 205-205.|[2]Carbajal K, et al. AR-13503 Enhances the efficacy of aflibercept in a mouse model of proliferative diabetic retinopathy[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 200-200.|[3]Halasz E, et al. AR-13503, a ROCK inhibitor, reduces rod axon retraction during retinal detachment[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 4221-4221.